

## **TITLE:**

**“Comparison between topical Platelet Rich Plasma and Normal Saline dressing, in conjunction with Total Contact Casting in Treatment of Diabetic Foot Ulcer– a Randomized Control Trial”**

## **RUNNING TITLE:**

**PRP and NS dressing in conjunction with TCC in DFU**

**Subha Das 1, Sanyal Kumar 2, Sanjay Kumar Pandey\* 3, Anjani Kumar 4, Niraj Kumar 5, Ranjeet Kumar 6**

1. MBBS MD (Senior Resident), Department of Physical Medicine and Rehabilitation, All India Institute of Medical Sciences, Patna, India.
2. MBBS, MD (Assistant Professor), Department of Physical Medicine and Rehabilitation, All India Institute of Medical Sciences, Patna, India.
3. MBBS, MD (Professor & Head), Department of Physical Medicine and Rehabilitation, All India Institute of Medical Sciences, Patna, India.
4. MBBS, MD (Assistant Professor), Department of Physical Medicine and Rehabilitation, All India Institute of Medical Sciences, Patna, India.
5. MBBS MD (Senior Resident), Department of Physical Medicine and Rehabilitation, All India Institute of Medical Sciences, Patna, India.
6. MBBS MD (Senior Resident), Department of Physical Medicine and Rehabilitation, All India Institute of Medical Sciences, Patna, India

\*Corresponding

Dr.Sanjay Kumar Pandey (Professor & Head)

Department of PM&R, All India Institute of Medical Sciences, Phulwari Sharif, Patna-801507, India, E-mail ID: [sanjaypandeyaiimspatna@gmail.com](mailto:sanjaypandeyaiimspatna@gmail.com) , Mobile: 8102922824.

## **CONFLICT OF INTEREST**

No Conflict of interest.

## **FUNDING**

No Funding was received.

## **AVAILABILITY OF DATA**

Data collected from department of PMR AIIMS Patna.

## **Data Access Statement**

All relevant data are within the paper and its Supporting Information files.

## **WORD COUNT**

Main manuscript word count:- 2741 (page 16)

**Author Contribution:** SD, NK contributed to the design and implemented research. SK, RK to the analysis and to the writing of the manuscript. SKP, AK conceived the original and supervised the project.

## **Abstract**

### **Introduction**

Wound care, which includes cleaning and fostering a moist wound healing environment, play a crucial role in the management of diabetic foot ulcers.. Total-contact casts are widely used as the most effective external technique for off-loading plantar ulcers. This study compared the effectiveness of PRP and normal saline dressings in conjunction with TCC.

### **Methods**

36 patients with diabetic foot ulcers were divided into two groups using computer generated randomization into PRP and NS groups with 18 patients in each group. The PRP group was given autologous PRP, and the NS group was given wet dressing with NS, following which TCC was applied in each case for off-loading. Follow-up was performed every 15 days for 90 days. In each follow-up measurement and TCC application, the time to heal and PUSH score was used to measure the condition of the wound.

### **Results**

In the PRP group, the mean wound size  $8.28 \pm 1.18$  and the mean Push tool total

13.44±0.98 at base line which gradually decreased, and finally, on day 90, it was reduced to 0.61±1.20 and 1.89±3.68, respectively. In NS group the mean wound size 8.45±1.13 and mean Push tool total 13.50±0.92 at baseline which was gradually decreased and finally at day 90 it was reduced to 1.58±1.55 and 4.61±4.37 respectively. A significant difference was observed in both groups during the final evaluation. Compared with the NS group, the PRP group showed greater improvement.

### **Conclusion**

Both autologous PRP and NS are effective in treating DFU, when used along with TCC. However, PRP therapy is better at reducing the healing time and hospital visits.

**Keywords:** Platelet rich plasma, Normal saline, total contact casting, Diabetic foot ulcer

### **Introduction**

The metabolic condition known as Type II diabetes mellitus (DM2) is characterized by hyperglycemia, followed by insulin resistance [1]. Numerous co-morbidities, including peripheral neuropathy, chronic renal failure, stroke, cardiovascular disease, and diabetic foot ulcers, are linked to type 2 diabetes mellitus [2]. The most common side effect of type 2 DM is diabetic foot ulcers (DFUs), which can result in repeated hospital visits, hospital stays, and financial strain for the patients [3]. Poor blood glucose management and high plantar pressure are the primary causes of DFUs, which are defined as full-thickness wounds that penetrate the dermis (deep vascular and collagenous inner skin layer) and are located below the ankle in diabetic patients [4,5]. Diabetic ulcers present as excruciating ulcers that break down dermal tissues, including the dermis, epidermis, and subcutaneous tissue. The non-healing phenotype of diabetic foot ulceration has been attributed to immune system dysfunction, microbial invasion, and epithelial disintegration. 25% of patients with diabetes have a life-time risk of developing diabetic foot ulcers, the majority of whom will require amputation within four years of the initial diagnosis [3]. Owing to their multi-factorial etiology, foot ulcers are difficult to treat and place a

significant burden on patients, health-care systems, and society [6]. Prevention is the key to managing diabetic foot wounds [7]. Patient education, regular foot examinations, and therapeutic foot-wear are essential to prevent DFU [7, 8]. Good clinical care entails frequent debridement, off-loading via casting with a walking rod, total contact cast (TCC), orthotic support, moist wound care with various dressing materials such as normal saline (NS), an antimicrobial agent, alginate, treatment of infection, and revascularization of the ischemic limb [9]. In severe wounds, however, vascular repair or amputation may be necessary [10, 11]. 15% of diabetic patients worldwide develop diabetic foot ulcers (DFU) at some point in their lives. An amputation of approximately 28% may be necessary [12]. The global prevalence of DFU is 6.3% in the overall population and is expected to increase in the future [13]. In India, the prevalence of diabetic foot ulcers is 4-5%, which is much lower than that reported in western countries [14].

## **Materials and Methods**

The study was conducted at a tertiary care center with a well-equipped research laboratory and other facilities for patient care after obtaining institutional ethical committee approval via AIIMS/Pat/IEC/PGTh/ July20/02 on September 29. The CONSORT statement requirements for reporting randomized controlled trials were followed, and the study complied with the principles of the Declaration of Helsinki. The clinical trial registration was performed (CTRI/2022/08/044973).

### **Study design and sample:**

This randomized clinical trial was conducted in the Department of Physical Medicine and Rehabilitation, All India Institute of Medical Science, Patna, India. The study population was estimated using statistical formulas, and 36 patients were included in each group based on sample size calculations. Convenient sampling was used to recruit cases after fulfilling the inclusion and exclusion criteria from October 2021 to November 2022. Written informed consent was obtained from all the

) patients. Each participant underwent a complete examination. Patients were  
.  
randomly assigned to two groups. The patients in the first group were administered  
:  
PRP therapy along with TCC, where as the patients in the second group were  
:  
administered NS dressing along with TCC. In this study, data will be collected, and  
.  
the outcome will be measured in terms of time to heal and the PUSH Tool 3.0. The  
:  
Statistical Package for the Social Sciences (SPSS) version 25 software will be used  
:  
for statistical analysis after the collection of all relevant data.

### **Study Procedure:**

) **PRP preparation and application:** Twenty milliliters of blood, taken from the  
:  
basilic antecubital veins, was placed into vacuum-sterilized test tubes together with  
)  
3.8 milliliters of sodium citrate to serve as an anticoagulant. Using an Eppendorf  
.  
Centrifuge 5720, the blood samples were centrifuged for 12 min at 1,200 rpm. Three  
:  
layers of blood were isolated: red blood cells were found in the bottom layer,  
:  
platelets and white blood cells were found in the thin middle layer, and white blood  
.  
cells (the buffy coat) were found in the upper layer. The upper and intermediate  
:  
buffy layers were then transferred to an empty sterile tube. To facilitate the  
:  
development of soft pellets (erythrocytes and platelets) at the bottom of the tube, the  
)  
plasma was centrifuged once more for seven minutes at 3,300 rpm; the upper two  
:  
thirds of the platelet-poor plasma was discarded; pellets were homogenized in the  
)  
lowest third (3mL) of the plasma to generate the PRP; the PRP was then extracted  
)  
using a 5 ml syringe [15]. After measuring the wound, proper cleaning and  
.  
debridement were performed. Freshly prepared autologous PRP was then applied to  
:  
the ulcer bed. The wound was covered with sterile, dry, gauze. After proper  
:  
covering, a total contact cast was applied for offloading ( Image1).

### **NS dressing application:**

) First the wound was measured. The wound was cleaned, debridement was  
:  
performed, and normal saline-soaked gauze was applied over the ulcer bed. The

wound was covered with sterile, dry gauze. After proper covering, a total contact cast was applied for offloading.

#### **TCC application:**

Inter-digital padding was applied first. Next, the stockinet was placed from the knee to the toes in a manner that showed the toes and prevented wrinkles or bunching. Layer of felt (D-filler) padding measuring 10-15 mm was positioned under the medial longitudinal arch. Cut to size, 5 mm silicone strips were placed across the bony prominences (e.g., medial/lateral malleoli, anterior tibia) [16]. Over the cushioning, a plaster of Paris cast was placed, extending one inch distal to the fibular head from the tips of the toes. To provide optimal contact, the cast was precisely shaped to fit the leg and foot [17, 18]. Patients were instructed to walk no more than one-third of their normal ambulation (Image 2).

#### **Follow-up and statistical analysis plan:**

Data collection (by “timetoheal” and “PUSHTool3.0”) will be performed at baseline and in the subsequent, 2 weekly follow-up, up to 3 months. In each follow-up measurement, debridement and TCC re-application were performed. The data were examined using IBM Corporation, Armonk; NYs, SPSS programme (version 23). A significance threshold of  $p < 0.05$  was established; the  $\chi^2$  test was employed to compare qualitative factors, while the Unpaired T-test was used to assess quantitative data. The standard deviation of the normal distribution of the quantitative variables was used to determine the significance level, which was set at  $p < 0.05$ .

## Results

In the PRP group, 11 (61.1%) patients were male and the remaining seven (38.9%) were female; in the NS group, 10(55.6%) were males and the remaining eight (44.4%) were females. Hence, in this study, 21 (58.3%) patients were males and 15 (41.7%) were females. The proportions of men and women in each group did not differ significantly ( $p = 0.735$ ). Hence, the groups were matched according to their sex. The left and right sides were involved in equal proportions in both PRP and NS groups. The mean age of the PRP group was  $56.50 \pm 4.96$  years, while that of the NS group was  $54.89 \pm 4.51$  years. No significant difference was found in the mean age between the PRP and NS groups ( $p = 0.315$ ). The mean BMI of the PRP group was  $26.07 \pm 3.70$  kg/m<sup>2</sup>, while the mean BMI of the NS group was  $25.17 \pm 3.28$  kg/m<sup>2</sup>. The PRP and NS groups mean BMIs did no significant differences ( $p=0.447$ ) (Figure 1). The mean duration of DM of PRP group was  $14.22 \pm 5.37$  years while the mean duration of DM of NS group was  $11.00 \pm 4.39$  years. No significant difference was found in the mean duration between the PRP and NS group ( $p=0.057$ ). The mean ABI of the PRP group was  $0.99 \pm 0.12$ , while the mean ABI of the NS group was  $0.98 \pm 0.15$ . No significant difference was found in the mean ABI between the PRP and NS group ( $p=0.811$ ). The mean HbA1c level of the PRP group was  $8.57 \pm 0.67$  while the mean HbA1c of the NS group was  $8.15 \pm 0.52$ . No significant difference was found in the mean HbA1c level between the PRP and NS group ( $p=0.53$ ). The mean RBS of the PRP group was  $217.22 \pm 27.78$  while the mean HbA1c of the NS group was  $208.00 \pm 23.51$ . No significant difference was found in the mean RBS between the PRP and NS group ( $p=0.290$ ). The mean platelet count of the PRP group was  $258.44 \pm 45.30$ , while that of the NS group was  $243.22 \pm 42.32$ . No significant difference was found in the mean platelet count between the PRP and NS group ( $p=0.305$ ). The mean albumin level in the PRP group was  $3.77 \pm 0.38$ , while that in the NS group was  $3.64 \pm 0.72$ . No significant difference was found in the mean platelet count between the PRP and NS group ( $p=0.508$ ). The mean time to heal in PRP group was  $11.17 \pm 2.73$  weeks while the mean time to heal in NS group was

13.78±1.66 weeks. A significant difference was found in the mean time to healing between the PRP and NS group (Table1). In PRP group the mean wound size at baseline was 8.28±1.18 which was gradually decreased and finally at day 90 it was reduced to 0.61±1.20. In NS group the mean wound size at baseline was 8.45±1.13 which was gradually decreased and finally at day 90 it was reduced to 1.58±1.55. The PRP and NS groups showed a significant difference in mean wound size at subsequent follow up period (Table 2). From baseline to every follow up intervals the mean change in wound size in the PRP and NS groups was significant ( $p<0.001$ ) (Table3). In PRP group the mean Push tool total at baseline was 13.44±0.98 which was gradually decreased and finally at day 90 it was reduced to 1.89±3.68. In NS group the mean Push tool total at baseline was 13.50±0.92 which was gradually decreased and finally at day 90 it was reduced to 4.61±4.37. Significant differences were found in the mean Push tool total between the PRP and NS groups on days 30 ( $p=0.015$ ), 45 ( $p=0.016$ ), 60 ( $p=0.003$ ), and 75 ( $p=0.002$ ) (Figure2). In the PRP and NS groups, the mean change in push tool total was significant from baseline to subsequent follow up periods ( $p<0.001$ ) (Figure3).

## Discussion

Diabetic foot ulcers are a major health concern that can lead to arthropathy and limb amputation [16]. Microangiopathy and macroangiopathy modify the vascular status and increase the risk of infection due to hyperglycemia; peripheral neuropathy in the diabetic foot results in excessive foot pressure, foot deformities, and unstable gait. Foot care and glycemic index management are crucial for preventing the development of foot ulcers [17]. Identification of the "at-risk" foot, treatment of the acutely diseased foot, and prevention of further complications are the three main strategies for managing diabetic foot disease to avoid amputation of the lower extremities [18]. In many cases, aggressive treatment of DFUs can prevent worsening of the condition and the potential need for amputation [19]. Therefore, the objective of therapy should be early



intervention to permit prompt healing of the lesion and once it has healed, to prevent its recurrence [20]. Platelet-rich plasma (PRP) is a portion of the plasma fraction of autologous blood with a platelet concentration above the baseline [21]. PRP is a growth factor agonist with mitogenic and chemo-tactic qualities that promotes wound healing via granules, which release locally acting growth factors [22, 23]. These growth factors promote tissue repair by attracting undifferentiated cells to the newly formed matrix and stimulating cell division [24]. Similar to the methods employed by Motolese et al., Shan et al., and Margolis et al., we used PRP as a gel dressing for DFU [25-27]. The gel was selected for practical use owing to its painless administration and patient preference. Moreover, compared to PRP injections into the floor and margins of the ulcer, the gel form might have a lower risk of infection. These factors increased the suitability of PRP gels for outpatient use. Since our institution uses normal saline as the standard dressing for DFU that are not infected, we decided to use it as the control group. In contrast to alternative therapeutic modalities that, while more successful, may have restricted access and high costs, especially in resource-constrained regions, this one is, after all, inexpensive, accessible, and easily available. Elsaid et al. found a similar proportion of sex ( $p=0.68$ ), mean age, and BMI in the PRP group and NS, which were not significant ( $p=0.74$ ) [28]. In this study, we found no statistical difference between the PRP and NS groups in terms of sex, size of the affected foot, age, BMI, duration of diabetes, ABI, RBS, HbA1C, serum albumin, or platelet count. Pressure reduction is an essential component in the treatment of diabetic foot ulcers. Total contact cast allows for mobility and relieves pressure over the ulcer, and has established the edit self as the gold standard for therapy, making patient adherence easier [29]. It has been shown to not only interrupt the pathogenesis chain that leads to ulceration but also induce changes in the histology of the ulcer [30]. The possible disadvantages of TCC include the need for specialized knowledge in its application,

) frequent cast replacements, and associated expenses [31]. According to Gupta et al;  
. the mean duration of DM in the PRP group was  $9.1\pm 5.1$  and in the NS group was  
:  $10.96\pm 5.42$ , which was not statistically significant [32].

) Ahmed et al. found that the mean ABI in the PRP group was  $0.85\pm 0.04$ , and that in  
. the NS group was  $0.83\pm 0.01$  with no statistically significant difference ( $p=0.881$ )  
: [33]. Elsaid et al; (2019) and Ahmad et al; (2017) used a sample with statistically  
: insignificant differences in HbA1c and mean RBS between the groups. The mean  
' platelet count of the PRP group was  $258.44\pm 45.30$ , while that of the NS group was  
:  $243.22\pm 42.32$ . No significant difference was found in the mean platelet count  
: between the PRP and NS group ( $p=0.305$ ), which is consistent with the finding of  
: Elsaid et al; (2019) and Ahmed et al; (2017), where p values were 0.78 and 0.42  
. respectively. Elsaid et al; (2019) also compared the mean serum albumin levels  
: between the PRP and NS groups, finding that they were  $4.15\pm 0.26$  and  $4.21\pm 0.42$ ,  
: respectively ( $p=0.68$ ). Additionally, they discovered that the PRP group's mean  
. duration to maximum healing was 4 weeks shorter than that of the control group  
: ( $6.3\pm 2.1$  vs.  $10.4\pm 1.7$  weeks,  $P<0.0001$ ). Likewise, Driver et al. showed that the PRP  
: group recovered 28 days faster on average than the control group [34]. These results  
' indicate that PRP's proliferative effect may improve DFU healing. A significant  
: difference was found in the mean time to healing between the PRP and NS group  
: ( $p=0.001$ ). Although it was statistically significant between the groups, it took much  
: more time than the study by Elsaid et al; which may be due to fewer applications of  
. PRP and keeping the wounds closed by TCC for 2 weeks and wound inspection was  
: not possible. In the PRP group, the total number of ulcers healed at 90 days was 14  
: out of 18 (77.78%), which was significantly better than that in the NS group (8 out  
. of 18 ulcers, (44.44%) ( $p<0.05$ ). This finding also correlates with the study by  
: Elsaid et al; however, in contrast with Gupta et al; this difference may be due to  
: differences in follow-up timings and different methods of application. When

specific PUSH variables were analyzed separately, only the length  $\times$  width decreased significantly among the healed ulcers. This may be due to the prevalence of stage 2 ulcers in the sample, the limited number of study ulcers with exudates, and the small number of categories used to distinguish changes in tissue type and exudate quantity. Gardner et al; (2005) found that the tissue type and exudate amount did not vary significantly at each follow-up, the only variable affecting the PUSH score was the tool's length  $\times$  width [35]. These parameters are consistent with the result of this study.

### **Conclusion**

In this study, we demonstrated that both PRP and NS dressings are beneficial and effective in the treatment of diabetic foot ulcers when used in conjunction with TCC to improve the healing rate. Although both treatments are beneficial, the results of this study indicated that PRP therapy is statistically superior to NS dressing. These results are consistent with those of the previous studies. The limitation of this study was the relatively short follow-up period. Diabetic foot ulcers can be chronic and slow healing wounds, often requiring extended periods for complete healing and for assessing the long-term efficacy of treatments. Therefore, a longer follow-up period would provide more comprehensive insights into the sustained effects of PRP therapy and NS dressing on diabetic foot ulcer healing rates.

### **References**

1. OkonkwoUA, DiPietroLA:DiabetesandWoundAngiogenesis.IntJMolSci.2017, 3; 18(7):1419.10.3390/ijms18071419.
2. LimJZ,NgNS,ThomasC:Preventionandtreatmentofdiabeticfootulcers.JRSocMed.2017,110(3):104- 109.10.1177/0141076816688346.
3. Volmer-Thole M, Lobmann R: Neuropathy and Diabetic Foot Syndrome. IntJMolSci.2016,10;17(6):917.10.3390/ijms17060917.
4. WenQ,ChenQ:An Overview of Ozone Therapy for Treating Foot Ulcers in Patients with Diabetes. AmJMedSci. 2020, 360(2):112-119.10.1016/j.amjms.2020.05.012.
5. ViswanathanV, SnehalathaC, SivagamiM, Seenar, Ramachandran A: Association

- of limited joint mobility and high plantar pressure in diabetic foot ulceration in Asian Indians. *Diabetes Res ClinPract.*2003,60(1):57-61.10.1016/s0168-8227(02)00272-3.
6. vanNetten JJ, Price PE, Lavery LA, Monteiro-Soares M, Rasmussen A, Jubiz Y, Bus S A: International Working Group on the Diabetic Foot. Prevention of foot ulcers in the at-risk patient with diabetes: a systematic review. *DiabetesMetabResRev.*2016, 32(1):84-92.10.1002/dmrr.2701.
  7. Nather A, Cao S, Chen JLW, Low AY: Prevention of diabetic foot complications. *SingaporeMedJ.*2018,59(6):291-294.10.11622/smedj.2018069.
  8. López-Moral M, Lázaro-Martínez JL,García-Morales E,García-Álvarez Y,Álvaro-Afonso FJ,Molines-Barroso RJ:Clinical efficacy of therapeutic footwear with a rigid rocker sole in the prevention of recurrencein patients with diabetes mellitus and diabetic polineuropathy: A randomized clinical trial. *PLoSOne.* 2019,7:14.10.1371/journal.pone.0219537.
  9. Kavitha KV, TiwariS, Purandare VB, Khedkar S, Bhosale SS, Unnikrishnan AG: Choice of wound care in diabetic foot ulcer: A practical approach. *WorldJDiabetes.*2014,15;5(4):546-56.10.4239/wjd.v5.i4.546.
  10. Thomas DR: Clinical management of diabetic ulcers. *ClinGeriatrMed.*2013, 29(2):433-41.10.1016/j.cger.2013.01.007.
  11. GuptaV,KakkarG,GillAS,GillCS,GuptaM:ComparativeStudyofNanocrystallineSilverIonDressingswith Normal Saline Dressings in Diabetic Foot Ulcers. *JCDR.*2018, 12(6):1-4.10.7860/JCDR/2018/36691.11590.
  12. BoultonAJ,VileikyteL,Ragnarson- TennvallG, ApelqvistJ: The global burden of diabetic foot disease. *Lancet.*2005,12;366(9498):1719-24.10.1016/S0140-6736(05)67698-2.
  13. ZhangP,LuJ,JingY,etal.:Global epidemiology of diabetic foot ulceration: a systematic review and meta-analysis. *AnnMed.*2017,49(2):106-116.10.1080/07853890.2016.1231932.
  14. KaleDS,KarandeGS,DatkhileKD: Diabetic Foot Ulcer in India: Aetiological Trends and Bacterial Diversity. *Indian J EndocrinolMetab.*2023, 27(2):107-114.10.4103/ijem.ijem\_458\_22.
  15. N.V.Ramanaiah,SaikrishnaS,ChandrasekharC,VamshidharV,GVRamanaiah,KLokesh:A Clinical Study on efficacy of Nanocrystalline silver dressing in Diabetic foot ulcer. *J of Evidence Based Med &Hlthcare.*2015, 45(2):8160-8170.
  16. HingoraniA,LaMuragliaGM,HenkeP,etal.:Themanagementofdiabeticfoot:Aclinical practiceguidelinebytheSocietyforVascularSurgeryincollaborationwiththeAmerican PodiatricMedicalAssociationandtheSocietyforVascularMedicine. *JVascSurg.*2016, 63(2):3S-21S.10.1016/j.jvs.2015.10.003.
  17. PourkazemiA,GhanbariA,KhojamliM,BaloH,HemmatiH,JafaryparvarZ,MotamedB :Diabeticfootcare:knowledge and practice. *BMC EndocrDisord.* 2020, 20(1):40.10.1186/s12902-020-0512-y.

18. Griffiths DA, Kaminski MR: Duration of total contact casting for resolution of acute Charcot foot: retrospective cohort study. *J Foot Ankle Res.* 2021, 14(1):41.10.1186/s13047-021-00477-5.
19. Sahu B, Prusty A, Tudu B: Total contact casting versus traditional dressing in diabetic foot ulcers. *J Orthop Surg.* 2018, 26(3):2309499018802486.10.1177/2309499018802486.
20. Petrova N, Edmonds M: Emerging drugs for diabetic foot ulcers. *Expert Opin Emerg Drugs.* 2006, 11(4):709-24.10.1517/14728214.11.4.709.
21. Marx RE: Platelet-rich plasma: evidence to support its use. *J Oral Maxillofac Surg.* 2004, 62(4):489-96.10.1016/j.joms.2003.12.003.
22. Bhanot S, Alex JC: Current applications of platelet gels in facial plastics surgery. *Facial Plast Surg.* 2002, 18(1):27-33.10.1055/s-2002-19824.
23. Piaggese A, Viacava P, Rizzo L, et al.: Semiquantitative analysis of the histopathological features of the neuropathic foot ulcer: effects of pressure relief. *Diabetes Care.* 2003, 26(11):3123-8.10.2337/diacare.26.11.3123.
24. David G, Armstrong DPM, Brian Short, Eric H, Espensen DPM, Patricia L, Abu-Rumman DPM, Brent P, Nixon DP M, Andrew J M, Boulton MD: Technique for Fabrication of an "Instant Total-Contact Cast" for Treatment of Neuropathic Diabetic Foot Ulcers. *Journal of the American Podiatric Medical Association.* 2002, 92(7):405-408.10.7547/87507315-92-7-405.
25. Motolese A, Vignati F, Antelmi A, Saturni V: Effectiveness of platelet-rich plasma in healing necrobiosis lipoidica diabetorum ulcers. *Clin Exp Dermatol.* 2015, 40(1):39-41.10.1111/ced.12474.
26. Shan GQ, Zhang YN, Ma J, et al.: Evaluation of the effects of homologous platelet gel on healing lower extremity wounds in patients with diabetes. *Int J Low Extrem Wounds.* 2013, 12(1):22-9.10.1177/1534734613477113.
27. Margolis DJ, Kantor J, Santanna J, Strom BL, Berlin JA: Effectiveness of platelet release for the treatment of diabetic neuropathic foot ulcers. *Diabetes Care.* 2021, 24(3):483-8.10.2337/diacare.24.3.483.
28. Elsaid A, ElSaid M, Emile S, Youssef M, Khafagy W, Elshobaky A: Randomized Controlled Trial on Autologous Platelet-Rich Plasma Versus Saline Dressing in Treatment of Non-healing Diabetic Foot Ulcers. *World J Surg.* 2020, 44(4):1294-1301.10.1007/s00268-019-05316-0.
29. Yazdanpanah L, Nasiri M, Adarvishi S: Literature review on the management of diabetic foot ulcer. *World J Diabetes.* 2015, 6(1):37-53.10.4239/wjd.v6.i1.37.
30. Martinez-Zapata MJ, Martí-Carvajal AJ, Solà I, et al.: Autologous platelet-rich plasma for treating chronic wounds. *Cochrane Database Syst Rev.* 2016, 25;2016(5):CD006899.10.1002/14651858.CD006899.
31. Braun LR, Fisk WA, Lev Tov H, Kirsner RS, Isseroff RR.: Diabetic foot ulcer: a evidence-based treatment update. *Am J Clin Dermatol.* 2014, 15(3):267-81.10.1007/s40257-014-

0081-9.

32. GuptaA,ChannaveeraC,SethiS,RangaS,AnandV:Efficacy of Intra-Lesional Platelet Rich Plasma in Diabetic Foot Ulcer. JAmPodiatrMedAssoc.2021,1;111(3):1-4.10.7547/19-149.
33. AhmedM,ReffatSA,HassanA,EskanderF:Platelet- Rich Plasma for the Treatment of Clean Diabetic Foot Ulcers. AnnVascSurg.2016,38:206-211.10.1016/j.avsg.2016.04.023.
34. DriverVR,HanftJ,FyellingCP,BeriouJM:Autologel Diabetic Foot Ulcer Study Group. A prospective, randomized, controlled trial of autologous platelet rich plasma gel for the treatment of diabetic foot ulcers. OstomyWoundManage.2006,52(6):68-70.
35. GardnerSE,FrantzRA,BergquistS,ShinCD:A prospective study of the pressure ulcer scale for healing (PUSH).JGerontolABiolSciMedSci.2005,60(1):93-7.10.1093/gerona/60.1.93.











FIGURE3: Distribution of Age & BMI in the groups



**FIGURE4: Push score total between PRP and NS groups.**




FIGURE5: Intragroup Comparison of Push tool total between PRP and NS groups.



Figure1: PRP Centrifugal machine (Eppendorf Centrifuge 5720), PRP and its application Method.



Figure 2: TCC application method

**Table–1: Intergroup Comparison of Time to Heal**

Intervention	Time to heal (weeks)		Unpaired test t-value	p-value
	Mean	SD		
PRP group	11.17	2.73	-3.467	0.001
NS group	11.78	1.66		

Wound Size	PRP group		NS group		t-value	p-value
	Mean	SD	Mean	SD		
baseline	8.28	1.18	8.45	1.13	-0.44	0.665
D15	7.70	1.17	8.19	1.28	-1.19	0.243
D30	5.92	1.58	7.76	1.46	-3.62	0.001
D45	4.43	1.75	6.40	1.40	-3.73	0.001
D60	2.83	1.78	4.86	1.38	-3.82	0.001
D75	1.32	1.79	3.24	1.60	-3.40	0.002
D90	0.61	1.20	1.58	1.55	-2.10	0.044

Wound Size	PRP group		NS group		t-value	p-value
	Mean	SD	Mean	SD		
baseline	7.72	0.46	7.56	0.51	1.03	0.312
D15	7.39	0.50	7.50	0.51	-0.66	0.516
D30	6.83	0.62	7.39	0.50	-2.96	0.006
D45	6.22	1.70	7.22	0.43	-2.42	0.021
D60	4.89	2.42	6.67	0.69	-3.00	0.005
D75	2.22	2.90	5.28	2.14	-3.60	0.001
D90	1.11	2.17	2.89	2.74	-2.16	0.038



Information to include when describing an intervention and the location of the information

Item number	Item	Where located **	
		Primary paper (page or appendix number)	Other †(details)
	<b>“Comparison between topical Platelet Rich Plasma and Normal Saline dressing, in conjunction with Total Contact Casting in Treatment of Diabetic Foot Ulcer– a Randomized Control Trial”</b>		
	<b>BRIEF NAME</b>		
1.	PRP dressing, NS dressing, Total contact casting	_____2_____	_____
	<b>WHY</b>		
2.	PRP, NS dressing and TCC used for the treatment of Diabetic foot ulcers. Very few study conducted for PRP and NS dressings in conjunction with TCC.	_____3_____	_____
	<b>WHAT</b>		
3.	Materials: Total contact Cast, Platelet rich plasma dressing, Normal saline dressing	_____3_____	_____
	<b>WHO PROVIDED</b>		
4.	Procedures: Dressing of wound with Normal saline and PRP followed by cast application	_____3_____	_____
	<b>HOW</b>		
5.	Resident doctor	_____3_____	_____
	<b>WHERE</b>		
6.	Hospital based, physically present	_____3_____	_____
	<b>WHEN and HOW MUCH</b>		
7.	Hospital based indoor department with equipped dressing room	_____3_____	_____
	<b>TAILORING</b>		
8.	Every 2 <sup>nd</sup> week, till 3 months (6 sessions)	_____4_____	_____

9.	PRP preparation, TCC application and NS dressing. Look the effect of PRP and NS dressings intervention in conjunction with TCC, Oct 2021 to Nov 2022, Hospital based	4	
<b>MODIFICATIONS</b>			
10. <input type="checkbox"/>	N/A		
<b>HOW WELL</b>			
11.	Planned: If intervention adherence or fidelity was assessed, describe how and by whom, and if any strategies were used to maintain or improve fidelity, describe them.: N/A		
12. <input type="checkbox"/>	Actual: If intervention adherence or fidelity was assessed, describe the extent to which the intervention was delivered as planned.: N/A		

\*\* **Authors** - use N/A if an item is not applicable for the intervention being described. **Reviewers** – use ‘?’ if information about the element is not reported/not sufficiently reported.

† If the information is not provided in the primary paper, give details of where this information is available. This may include locations such as a published protocol or other published papers (provide citation details) or a website (provide the URL).

If completing the TIDieR checklist for a protocol, these items are not relevant to the protocol and cannot be described until the study is complete.

\* We strongly recommend using this checklist in conjunction with the TIDieR guide (see *BMJ* 2014;348:g1687) which contains an explanation and elaboration for each item.

\* The focus of TIDieR is on reporting details of the intervention elements (and where relevant, comparison elements) of a study. Other elements and methodological features of studies are covered by other reporting statements and checklists and have not been duplicated as part of the TIDieR checklist. When a **randomised trial** is being reported, the TIDieR checklist should be used in conjunction with the CONSORT statement (see [www.consort-statement.org](http://www.consort-statement.org)) as an extension of **Item 5 of the CONSORT 2010 Statement**. When a **clinical trial protocol** is being reported, the TIDieR checklist should be used in conjunction with the SPIRIT statement as an extension of **Item 11 of the SPIRIT 2013 Statement** (see [www.spirit-statement.org](http://www.spirit-statement.org)). For alternate study designs, TIDieR can be used in conjunction with the appropriate checklist for that study design (see [www.equator-network.org](http://www.equator-network.org)).